Media stories about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.6988341521787 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Catalyst (CPRX) Up on New Drug Application for Firdapse (finance.yahoo.com)
- BioMarin Pharmaceutical (BMRN) PT Set at $130.00 by JPMorgan Chase (americanbankingnews.com)
- BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $169,774.28 in Stock (americanbankingnews.com)
- BioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 10,000 Shares (americanbankingnews.com)
- BioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017 (finance.yahoo.com)
Shares of BioMarin Pharmaceutical stock traded down $2.69 on Friday, hitting $76.01. The stock had a trading volume of 1,284,647 shares, compared to its average volume of 1,343,170. BioMarin Pharmaceutical has a 52-week low of $75.81 and a 52-week high of $100.51. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.12 and a current ratio of 2.70. The company has a market capitalization of $13,934.36, a P/E ratio of -113.45 and a beta of 1.69.
A number of brokerages have issued reports on BMRN. BidaskClub raised BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, December 16th. JPMorgan Chase decreased their price target on BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a report on Wednesday, January 24th. Wedbush reaffirmed an “outperform” rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, December 22nd. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Finally, Piper Jaffray reaffirmed a “buy” rating and set a $114.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $112.34.
In related news, EVP Jeffrey Robert Ajer sold 2,119 shares of the business’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $80.12, for a total value of $169,774.28. Following the transaction, the executive vice president now owns 52,914 shares in the company, valued at approximately $4,239,469.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Eric Davis sold 2,105 shares of the business’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $79.04, for a total value of $166,379.20. Following the completion of the transaction, the executive vice president now owns 90,089 shares in the company, valued at approximately $7,120,634.56. The disclosure for this sale can be found here. Insiders sold a total of 85,269 shares of company stock valued at $7,301,002 over the last three months. Company insiders own 1.85% of the company’s stock.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.